Biology and therapy of primary mediastinal B‐cell lymphoma: current status and future directions. (10th February 2019)

• Record Type: Journal Article
• Authors: Lees, Charlotte; Keane, Colm; Gandhi, Maher K.; Gunawardana, Jay
• Is Part Of: British journal of haematology. Volume 185:Number 1(2019)
• Page Start: 25
• Page End: 41
• Publication Date: 2019-02-10
• Subjects: non‐Hodgkin lymphoma -- tumour immunotherapy -- haematological oncology -- tumour biology -- malignant lymphomas; Hematology -- Periodicals; Blood -- Diseases -- Periodicals; 616.15
• DOI: 10.1111/bjh.15778
• Languages: English
• ISSNs: 0007-1048

Abstract

Summary: Primary mediastinal B‐cell lymphoma (PMBCL) is a distinct disease closely related to classical nodular sclerosing Hodgkin lymphoma. Conventional diagnostic paradigms utilising clinical, morphological and immunophenotypical features can be challenging due to overlapping features with other B‐cell lymphomas. Reliable diagnostic and prognostic biomarkers that are applicable to the conventional diagnostic laboratory are largely lacking. Nuclear factor kappa B (NF‐κB) and Janus kinase/signal transducers and activators of transcription (JAK‐STAT) signalling pathways are characteristically dysregulated in PMBCL and implicated in several aspects of disease pathogenesis, and the latter pathway in host immune evasion. The tumour microenvironment is manipulated by PMBCL tumours to avoid T‐cell mediated destruction via strategies that include loss of tumour cell antigenicity, T‐cell exhaustion and activation of suppressive T‐regulatory cells. R‐CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisolone) and DA‐EPOCH‐R (dose‐adjusted etoposide, prednisolone, vincristine, cyclophosphamide, doxorubicin, rituximab) are the most common first‐line immunochemotherapy regimens. End of treatment positron emission tomography scans are the recommended imaging modality and are being evaluated to stratify patients for radiotherapy. Relapsed/refractory disease has a relatively poor outcome despite salvage immunochemotherapy and subsequent autologous stem cell transplantation. Novel therapies are therefore being developed for treatment‐resistant disease, targeting aberrant cellular signalling and immune evasion.